| Nov 5 |
Ionis Pharmaceuticals Q3 2024 Earnings Preview
|
| Nov 4 |
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
|
| Nov 4 |
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
|
| Oct 31 |
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
|
| Oct 30 |
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Oct 25 |
Ionis: Expect More Of The Same In Terms Of Earnings, Despite Regulatory Successes
|
| Oct 23 |
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
|
| Oct 23 |
Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years
|
| Oct 23 |
Ionis to hold third quarter 2024 financial results webcast
|
| Oct 22 |
EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN
|
